Oxford Vaccines Group begins Phase 2 study of Ebola vaccines

Oxford Vaccines Group begins phase 2 study of Ebola vaccine MVA-BN® and AdVac®
Oxford Vaccines Group begins phase 2 study of Ebola vaccine MVA-BN® and AdVac® | Courtesy of
Bavarian Nordic, the Oxford Vaccines Group recently started its Phase 2 clinical study involving a combination of Bavarian Nordic’s MVA-BN Filo vaccine and Janssen’s Ad26.ZEBOV vaccine.

Combining MVA-BN and AdVac (produced by Johnson & Johnson, a branch of Janssen Pharmaceutical Companies) creates a prime-boost vaccine regimen for Ebola.

Researchers have administered the initial vaccine dose to the first volunteers of the study. Preliminary data, which was taken from the first in-human Phase 1 study, was presented to the Food and Drug Administration (FDA) Advisory Committee by Janssen this past May. The data suggests that the new prime-boost vaccine regimen is effectively immunogenic, despite the vaccine administration order. The administration induced only temporary reactions that are typically expected of a vaccine.

"We are pleased to report further progress in the clinical development of the prime-boost Ebola vaccine regimen which is being led by our partner Janssen,” Bavarian Nordic CEO and President Paul Chaplin said. “Vaccines play an essential role in outbreak situations, and both the clinical and the manufacturing experience we gain through this accelerated development represent an important piece of work in the combined efforts to ensure preparedness against Ebola, now and in the future."

Organizations in this Story

Bavarian Nordic

Want to get notified whenever we write about Bavarian Nordic ?
Next time we write about Bavarian Nordic, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.